Kelly McCormick

Cooley advised Tvardi Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the development of novel, oral, small-molecule therapies targeting STAT3 to treat fibrosis-driven diseases, on its definitive merger agreement to combine in an all-stock transaction with Cara Therapeutics (Nasdaq: CARA), a development-stage biopharmaceutical company that has been leading a new treatment paradigm to improve the lives of patients suffering from pruritus.

Cooley advised Cresta, an end-to-end generative artificial intelligence (AI) platform for contact centers, on the closing of its $125 million Series D.

Cooley advised Hadrian Automation – a company building highly automated factories to accelerate the entire advanced manufacturing sector and bring the future forward faster – on its $117 million Series B financing. Lawyers Peter Werner, Zander Olsson, Carl Min and Erin Wright led the Cooley team advising Hadrian.

Cooley advised Tetra Tech, a leading global provider of consulting and engineering services that focuses on water, environment, sustainable infrastructure, renewable energy and international development, on its Rule 144A offering of $575 million aggregate principal amount of 2.25% convertible senior notes due 2028, which includes the full exercise of the initial purchasers’ option to purchase an additional $75 million aggregate principal amount of notes. Partners John-Paul Motley, Mischi a Marca, Jason Savich, Ellie Guadiana and Logan Tiari led the Cooley team advising Tetra Tech.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.